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The primary aim of our study was to prospectively study patients with CRS and comorbid asthma to examine validated, asthma-specific outcomes after ESS. Our secondary aims were to determine pre-operative factors predictive of the severity of baseline asthma QOL and control, as well as factors predictive of asthma-specific outcomes after ESS.
Materials and methods

Patient population and study inclusion criteria
Adult patients (>18 years of age) were recruited into a prospective, multicenter, observational cohort study to evaluate treatment outcomes for CRS. The Institutional Review Board (IRB) at each enrollment center governed study protocols and annual safety monitoring. Previous outcome findings from this cohort have been reported (5, 6) . Enrollment centers consisted of sinus surgical centers located within academic hospitals in North America including: Oregon Health & Science University (OHSU; Portland, OR), Stanford University (Palo Alto, CA), the Medical University of South Carolina (Charleston, SC), and the University of Calgary (Calgary, Alberta, Canada). Patients were asked to provide a comprehensive assessment of medical comorbidity and social history during baseline interview and enrollment meetings. Study participants with CRS were included if diagnosed with current comorbid asthma as indicated by either physician diagnosis and active therapeutic treatment or prior lung function study.
All participants were diagnosed with medically recalcitrant CRS as defined by the American Academy of Otolaryngology -Head and Neck Surgery (7, 8) and European Position Paper 2012 (9) . All patients reported continuing 'cardinal symptoms' associated with CRS. Study participants completed initial trials of medical therapy including: at least one course of either topical corticosteroids (≥21 days) or a 5-day course of oral corticosteroids, and at least one course (≥14-days) of culture-directed or broad spectrum antibiotics per the standard of care. Participants voluntarily selected ESS as treatment for improved mitigation of symptoms. Postoperative therapeutics included daily nasal saline irrigations and appropriate continued medical therapy, as needed, for targeted symptom resolution and optimal postoperative healing.
Exclusion criteria
Participants were excluded from the final analysis if they failed to complete study-related evaluations correctly, without errors or omissions, and were considered lost to follow up if they did not complete follow-up evaluations at least 6 months after initial baseline evaluations. Additional exclusions included study participants with any variant of comorbid ciliary dyskinesia or cystic fibrosis.
Evaluations of asthma severity
Considered the main outcomes of interest, two complementary, patient-based outcome tools were utilized to identify the severity of comorbid asthma in this patient population: the Mini Asthma Quality of Life Questionnaire (miniAQLQ) and the Asthma Control Test (ACT). The miniAQLQ is a validated 15-item self-administered survey used to describe both the symptom severity and limitation as a result of asthma during the preceding 2-week period, using summarized Likert response scales (range: 1-7) (10). The miniAQLQ consists of four domains including: symptoms (five items), activity (four items), emotional function (three items), and environmental stimuli (three items). Higher total scores on the miniAQLQ and its domains are reflective of better QOL and less asthmarelated impairment. Score change of at least 0.50 points has been previously defined as minimal clinically important difference (MCID).
The second asthma-specific outcome was the ACT, a validated, self-administered survey tool used to assess a patients' perception of disease control over the preceding 4-week period using Likert scale responses (range: 0-5) (11). The ACT consists of five items regarding the frequency of asthma-related symptoms, the need for rescue medications, and perceived control of disease. Higher total scores (range: 0-25) indicate better levels of asthma control, however scores <20 reflect uncontrolled asthma at the time of completion. Score change of at least 3 points has been previously defined as MCID.
CRS-specific quality-of-life evaluation
Disease-specific QOL was evaluated using the 22-item SinoNasal Outcome Test (SNOT-22), a validated instrument developed to quantify symptom severity associated with sinonasal conditions (©2006; Washington University, St. Louis, MO, USA) (12). Item scores are categorized using patient selected Likert scale responses (item score range: 0-5) where higher scores indicate worse symptom severity.
Clinical measures of CRS
Per the standard of care, high-resolution computed tomography (CT) without contrast was used to assess sinonasal disease severity using 1 mm contiguous images in the axial plane. Bilateral image staging was completed by each enrolling physician in accordance with the Lund-Mackay scoring system (range: 0-24) which estimates opacification severity in the maxillary, ethmoidal, sphenoidal, ostiomeatal complex, and frontal sinus regions (13) .
Sinonasal regions were also evaluated using rigid, fiberoptic endoscopes (Karl Storz, Tuttlingen, Germany). Bilateral endoscopic examinations were staged by each enrolling physician using the Lund-Kennedy scoring system (range: 0-20) which estimates pathologic characteristics within the paranasal sinuses including the severity of nasal polyposis, discharge, edema, scarring, and crusting (13) . Higher total scores on both staging systems represent worse overall disease severity.
Data management and statistical analyses
Protected health information was removed, and study data were safeguarded using unique study identification number assignment for each participant. Study data were securely to OHSU from each performance site for manual entry into a Health Insurance Portability and Accountability Act (HIPAA) compliant, relational database (Access; Microsoft Corp, Redmond, WA, USA). All statistical analyses were completed using commercially available software (SPSS version 22.0; IBM Corporation, Armonk, NY, USA). Study data were evaluated descriptively (means, standard deviations, ranges, and prevalence), while assumptions of distribution normality were verified for all ordinal and continuous measures. Postoperative asthma-specific outcome scores were operationalized using last available response, and postoperative change scores were calculated by subtracting pre-operative scores from last postoperative scores.
Matched pairing t-test statistics and Wilcoxon signed-rank test to evaluate within-subjects improvement over time across asthma-specific and CRS-specific QOL scores. Independent ttesting or Mann-Whitney U-testing was used to compare improvement between discrete subgroups, and two-tailed Spearman's rank correlation coefficients (Rs) were used to evaluate the magnitude of associations between continuous independent variables and postoperative changes in asthmaspecific outcome measures.
Basic, stepwise, linear regression was used to identify significant cofactors associated with pre-operative patient-reported asthma severity, as measured by the miniAQLQ and ACT total scores. Following univariate screening of potential cofactors (P < 0.250), final models were constructed using manual forward selection (P < 0.100) and backwards elimination (P < 0.050). Coefficient of multiple determination (R 2 ) to evaluate goodness of model fit and the proportion of total variation in the dependent variable explained by model cofactors. Multicollinearity between significant cofactors was evaluated with variance inflation factors (VIFs), and final model diagnostics were performed to confirm assumptions of error normality and independence using residual and normal probability ('quantilequantile' plots). Regression effect estimates (b), standard errors, 95% confidence intervals, and estimates of type I error (P-values) are reported, where appropriate, for all results.
Results
Baseline study population
A total of 86 study participants with CRS and comorbid asthma met inclusion criteria, completed baseline asthma severity evaluations, and were prospectively enrolled between October 2012 and June 2015. Overall demographics, prevalence of treatment modality, comorbid disease characteristics, evaluations of asthma severity, and CRS-specific disease severity measures are described for all study participants in Table 1 . The mean miniAQLQ was 4.6 AE 1.4, and the mean ACT was 18.4 AE 5.3, with 51% reporting uncontrolled asthma (ACT < 20).
Postoperative changes in asthma and CRS outcomes
Postoperative asthma outcomes using the miniAQLQ were available on 61 of 86 (71%) patients undergoing ESS for an average of 13.7 (AE5.1) months (range: 4-25 months). There were no significant differences in baseline miniAQLQ (4.6 AE 1.3 vs 4.5 AE 1.5; P = 0.795) or ACT scores (18.5 AE 4.9 vs 18.0 AE 6.0; P = 0.711) between subjects who followed up and those lost to follow up. Average within-subjects postsurgical improvements were reported in miniAQLQ scores (mean change: 0.5 AE 1.1, P = 0.002) and ACT scores (mean change: 1.3 AE 4.1, P = 0.025, Table 2 ). When examining the prevalence of patients reporting at least one MCID for the miniAQLQ and ACT total scores, a total of 27/61 (44%) of study participants reported postoperative improvement of at least 0.5 units on the miniAQLQ, while 16/52 (31%) reported improvement of at least 3.0 units on ACT total scores.
Patients with pre-operative uncontrolled asthma as defined by pre-operative ACT total scores (<20) had even greater improvements in both miniAQLQ scores (mean change: 0.7 AE 1.3, P = 0.004) and ACT scores (mean change: 2.9 AE 4.4, P = 0.002, Table 2 ). The prevalence of uncontrolled comorbid asthma, as evaluated by the ACT, decreased from 51% to 32% after ESS (P = 0.004). When examining CRS patients with pre-operative uncontrolled asthma, a total of 57% of patients reported an MCID on miniAQLQ total scores, while 50% reported an MCID on ACT total scores.
Chronic rhinosinusitis-specific outcomes also significantly improved, with a mean change in SNOT-22 total score of 33.8 AE 22.8 (P < 0.001).
Predictors of baseline asthma severity
Given that both asthma-specific outcomes improved after ESS, we further sought to determine factors which would aid clinicians in predicting both baseline asthma severity and asthma-specific improvement after ESS. Average baseline miniAQLQ and ACT total scores were evaluated across patient cofactors to assess the associations between those cofactors and the asthma-related outcome measures of interest. Without multivariate adjustment, independent subgroups with comorbid allergy and chronic obstructive pulmonary disease (COPD) reported significantly worse miniAQLQ total scores compared to subjects without those comorbidities. Also, subgroups of participants with comorbid COPD reported significantly worse asthma control as measured by average ACT total scores at baseline, compared to subjects without. Significant, but weak, correlations were also found between total scores of the SNOT-22 and CT score and both the miniAQLQ and ACT survey responses (Rs ≤ À0.246; P ≤ 0.031).
After manual control and adjustment for enrollment site variation, simple linear regression was able to identify statistically significant clinical factors associated with both worse miniAQLQ (Table 3) and ACT (Table 4 ) total scores at baseline. Chronic obstructive pulmonary disease was associated with both asthma patient reported outcome measures (PROMs), and allergy was associated with miniAQLQ. No other CRS-specific factors, including SNOT-22 or CT score, were associated with asthma PROMs. No evidence of multicollinearity was found between any final model cofactors (VIFs < 2.0) and while residual and normal probability plotting suggested normal error distribution for both final models.
Predictors of postoperative improvement in comorbid asthma severity
Baseline cofactors, as well as measures of disease-specific QOL and asthma severity, were compared between participants with and without postsurgical follow-up. Study participants who voluntarily provided study follow-up were found to be significantly older, on average, compared to participants who did not return for study follow-up [49.4 (AE15.9) vs 41.6 (AE13.4) years; P = 0.035]. Study participants were similar in regard to all other study cofactors, disease-specific QOL scores, and measures of baseline asthma severity on average (all P ≥ 0.082).
Average postoperative differences in miniAQLQ (n = 61) and ACT total scores (n = 52) were evaluated across other patient cofactors to assess differences between independent cofactors and the primary outcomes of interest and to identify potential significant predictors of asthma-related QOL improvement following sinus surgery (Tables 5 and 6 ). Multivariate adjustment was not performed due to the limited numbers of patients and the large numbers of cofactors; however, without multivariate adjustment, subgroups of study participants with corticosteroid-dependent conditions reported significant post-treatment worsening on miniAQLQ total scores compared to subjects not using regular corticosteroid therapies. Improvement in miniAQLQ scores was associated with improvement in total SNOT-22 scores after ESS. Also without multivariate adjustments, subgroups of participants with obstructive sleep apnea reported significant postoperative worsening in asthma control as measured by ACT total scores compared to subjects without. Not unexpectedly, patients with uncontrolled asthma at baseline received the greatest benefit in both miniAQLQ scores, as well as ACT scores, after ESS. 
Discussion
Our study demonstrated that patients with pre-existing asthma and CRS experience improved asthma-specific QOL and asthma control after ESS. This supports the findings of recent meta-analyses that ESS improves asthma symptoms(2, 3), but we have now demonstrated this in a prospective fashion with validated asthma-specific outcome metrics. When comparing our outcomes to prior reports, it is important to note the apparent differences in severity of asthma in various publications. Our baseline cohort had fairly severe asthma, with 19% steroid dependency (n = 10 for asthma, n = 5 for Rs, Spearman's rank correlation coefficient (two-tailed). Cofactors do not represent mutually exclusive subgroups. Negative scores reflect postoperative worsening on average. Between-subject differences were evaluated using either independent t-testing or Mann-Whitney U-testing, depending on distribution normality. Bold values indicate statistical significance.
CRS, and n = 1 for vocal cord dysfunction) and was not limited by polyp status or aspirin sensitivity. Fifty-one percent of our patients had uncontrolled asthma with ACT scores <20, and 19% had aspirin exacerbated respiratory disease (AERD). As shown in Table 2 , this uncontrolled group demonstrated greater improvements after ESS in every domain of the miniAQLQ, as well as the ACT, when compared to the overall group. This is not unexpected, as patients with well-controlled asthma have less room for reportable improvement than those with uncontrolled asthma (i.e. a ceiling effect). Additionally, it is possible that our findings are a demonstration of regression to the mean, as asthma is a dynamic disease and a significant number of patients with uncontrolled asthma at baseline may have improved independent of surgery. Future studies with observational and/or medically treated arms for comparison will be useful. Chen et al. (14) previously examined ACT outcomes after ESS. They demonstrated improvement in ACT categorization of asthma control, but failed to show improvement in mean postoperative ACT scores. In their study cohort, only 11% of patients had poorly controlled asthma pre-operatively, compared to 51% of our patients. Additionally, their mean pre-operative ACT score was 22.1 of a maximum possible score of 25, compared to 18.4 in our study, further demonstrating poorer pre-operative asthma control in our patient cohort. Given the relatively well-controlled baseline asthma in the Chen study, it is not surprising that there was little room for additional improvement after ESS. While absolute changes in QOL and control metrics are important, likelihood of achieving an MCID is also important for pre-operative counseling. Approximately half of our patients with uncontrolled baseline asthma achieved an MCID in both miniAQLQ and ACT.
Other studies have examined asthma symptoms after ESS using nonvalidated metrics. Ehnhage studied CRS with nasal polyp (CRSwNP) patients who were not steroid dependent and found improvements in asthma symptoms and pulmonary function tests (PFTs) (15, 16) . Batra examined one of the most severe cohorts limited to steroid-dependent asthmatics with CRSwNP and reported improved PFTs and steroid dependency (17) . While these studies did not report validated asthma QOL or control instruments, in general they support our findings.
Having found that asthma outcomes improve after ESS, one of our secondary goals was to seek pre-operative factors that could aid clinicians in identifying the severity of baseline asthma QOL and control. Chronic obstructive pulmonary disease was associated with both baseline miniAQLQ and ACT scores, and allergies were associated with miniAQLQ scores. This is not surprising given the likely impact of these additional co-morbidities upon patient-reported outcome measures assessing QOL and control of a pulmonary condition. Initial bivariate analysis suggested sinus CT score and baseline SNOT-22 may be associated, but these variables become nonsignificant in the regression modeling. Thus, despite previous reports regarding the increased prevalence of asthma patients with nasal polyps or atopy (1), we were only able to identify an association between atopy and asthma severity as assessed by miniAQLQ scores. Polyp status did not correlate with any metrics of asthma severity. One prior study by Lin et al. (18) did look at asthma severity, but rather than using miniAQLQ or ACT, they classified asthma severity into two groups (intermittent/mild vs moderate/severe) using National Institutes of Health clinical guidelines based upon frequency and severity of symptoms. They studied patients presenting with CRS and nearly 75% did not have any asthma. Of the 47 patients with asthma, 38% were clinically classified with moderate/severe asthma. They found that as asthma severity increased, the prevalence of allergies, polyps, and CT score increased. The strength of their study was clinical classification by asthma specialists, but it is not known if this clinical classification correlates with the validated miniAQLQ or ACT in this patient population. Additionally, it is unknown if these associations would still be present if they had limited their study to patients with preexisting asthma as we did or if their findings were driven by the large numbers of nonasthmatic patients in the study.
In addition to looking for factors associated with baseline asthma severity, we examined pre-operative factors that could potentially aid clinicians in predicting asthma-specific outcomes after ESS. As shown in Tables 5 and 6 , the only variables that were associated with improved asthma outcomes after ESS were lack of corticosteroid dependency, postoperative change in total SNOT-22 (miniAQLQ), and lack of obstructive sleep apnea (ACT). The impact of steroid dependence and obstructive sleep apnea (OSA) is not surprising given the severity of those associated comorbidities. The correlation between improvements in SNOT-22 and miniAQLQ could be interpreted in a couple of ways. It could be that improvements in upper airway symptoms truly drive improvements in the lower airway. Alternatively, both instruments contain overlapping systemic domains, including sleep and psychological aspects, thus improvements in systemic domains after ESS would be reflected in improved miniAQLQ scores as well as total SNOT-22 scores. Further study into which subdomains are driving these associations remains an area for further research. Due to limited numbers, we were unable to perform regression models for postoperative outcomes. While there were no novel factors predictive of asthma outcomes after ESS, this indicates similar benefit across all groups, including those with atopy, AERD, and polyposis.
One weakness of our study is lack of medication usage specifically for asthma. Prior meta-analyses of asthma outcomes after ESS found that hospitalizations and medication usage decreased (2, 3) . In many cases, it may be difficult to separate the indications for medication usage, such as systemic steroids, as patients are often placed on these medications for both sinus and asthma symptoms. One advantage in our use of the ACT was that it contains a question specifically inquiring about use of rescue inhalers, thus demonstrating some benefit in asthma-specific medications. However, it is possible that patients on oral steroids used fewer rescue inhalers, artificially improving their ACT and miniAQLQ scores. These medications are also prescribed by a variety of healthcare providers, including primary care physicians, otolaryngologists, and asthma/allergy specialists, making precise indications for their use difficult to ascertain. Additionally, our study lacked PFTs. Prior meta-analyses report that PFTs typically do not change after ESS (2, 3). Combining our results using validated asthma QOL and control instruments, with other outcomes, including PFTs, hospitalizations and asthma-specific medication usage remain an interesting area for future research. Our study also relied upon prior physician diagnosis of asthma, rather than confirming this diagnosis with PFTs and bronchodilator response, and thus, some patients may have been misdiagnosed. Finally, the results of our study should be limited to similar populations -patients presenting with symptomatic CRS that has failed appropriate medical therapy and have comorbid asthma. Asthma-specific outcomes in other populations, such as CRS patients who are asymptomatic or who have not undergone medical therapy for CRS, are unknown.
Our findings that ESS improves asthma-specific outcomes parallel that of many studies of ESS for CRS-specific outcomes (6, 19, 20) . It is consistently reported that ESS improves CRS-specific QOL, yet these PROMs correlate weakly, if at all, with objective CRS-specific clinical metrics, including CT, endoscopy, polyp status or atopy, and physicians are still left with few prognostic factors to aid in guiding treatment decisions. Our study now confirms that surgical treatment of symptomatic CRS does improve asthma-specific outcomes, yet factors which predict severity of QOL and provide prognostic information regarding treatment outcomes remain unknown. Studies using cluster analysis for novel classification and prognostication have been performed, both in CRS and asthma (6, 21 ). It appears that some clinical factors provide prognostic information in these diseases. Future studies combining refined clinical categorization of both upper and lower airway disease with enhanced endotyping will likely improve our ability to provide individualized medicine for patients with comorbid respiratory tract disease.
Recent studies have reported that early ESS for symptomatic CRS may decrease the development of asthma (22) (23) (24) . Our study population was limited to patients with preexisting asthma, so unfortunately we are unable to determine the relationship between the timing of ESS, duration of preexisting asthma, its severity, or the impact upon ESS outcomes, but this remains an interesting area for further studies.
Conclusion
Patients presenting with CRS refractory to medical therapy and co-existent asthma who undergo ESS experience improvement in asthma QOL and control. This benefit is most evident in patients with uncontrolled pre-operative asthma. Further correlation to PFTs, medication usage, and healthcare utilization are needed.
